Cannabidiol

證據等級: L5

預測適應症: 0 個

Cannabidiol: Preliminary Assessment — No TxGNN Prediction Data Available

One-Sentence Summary

Cannabidiol (CBD) is a phytocannabinoid derived from Cannabis sativa, with established regulatory approval in major markets (FDA: Epidiolex; EMA: Epidyolex) for treatment-resistant epilepsy syndromes. This Evidence Pack contains no TxGNN predicted indications, and critical data — including mechanism of action, Germany market authorization records, and safety profile — are flagged as blocking gaps. A full drug repurposing evaluation cannot be completed until these data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Treatment-resistant epilepsy (Dravet syndrome, Lennox-Gastaut syndrome) — based on expert knowledge; not confirmed in Evidence Pack
Predicted New Indication	No predictions available
TxGNN Prediction Score	N/A
Evidence Level	N/A — no predictions generated
Germany Market Status	Not found (Evidence Pack: 未上市 / 0 authorizations)
Number of Authorizations	0
Recommended Decision	Hold

Data Gap Summary

This Evidence Pack has 2 blocking/high-severity data gaps that prevent a complete evaluation:

Gap ID	Item	Severity	Impact	Remediation
DG001	Package insert warnings / contraindications	Blocking	Cannot pass S1 safety gate	Download EMA Epidyolex SmPC PDF and parse
DG002	Mechanism of action (MOA)	High	Cannot perform mechanistic relevance analysis	Query DrugBank API for DB09061

Why No Prediction Is Available

The TxGNN model returned no predicted indications for Cannabidiol (DB09061) in this run. Possible reasons include:

The compound is not present in the knowledge graph used during this prediction run
All candidate scores fell below the reporting threshold
A pipeline error occurred upstream of the evidence collection step

Without at least one TxGNN predicted indication, the core drug repurposing analysis cannot proceed. This must be investigated before any further evaluation steps are taken.

Germany Market Information

No authorization records were found for Cannabidiol in the regulatory database within this Evidence Pack.

Discrepancy note: Epidyolex (cannabidiol oral solution 100 mg/mL) received EMA approval on 19 September 2019 for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged ≥2 years. The absence of records strongly suggests the regulatory query was run under the INN "CANNABIDIOL" but failed to match the approved brand name. The query should be re-run using alternative identifiers: Epidyolex, Epidiolex, or marketing authorisation number EU/1/19/1375.

Safety Considerations

All safety data fields in this Evidence Pack are unavailable. Please refer to the official EMA Summary of Product Characteristics (SmPC) for Epidyolex for complete safety information.

Blocking item outstanding before evaluation can proceed: DG001 — Retrieve and parse the Epidyolex SmPC to extract contraindications, warnings, and key drug interactions (particularly with CYP3A4/CYP2C19 substrates and valproate).

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is missing TxGNN predictions entirely, and two blocking/high-severity data gaps (MOA, safety profile) prevent any meaningful drug repurposing assessment from being conducted at this stage.

To proceed, the following is needed:

[Critical] Re-run TxGNN prediction pipeline for DB09061 and confirm that output is non-empty; if still empty, verify compound is included in the knowledge graph
[DG001] Retrieve the Epidyolex EMA SmPC (EU/1/19/1375) and extract warnings, contraindications, and drug interaction profile
[DG002] Query DrugBank API for full MOA data for DB09061 (cannabidiol)
[Regulatory] Re-run the Germany regulatory query using brand names Epidyolex / Epidiolex to retrieve actual market authorization records and approved indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.